"Klinika Okulistyczna OFTALMIKA w Bydgoszczy jest jednym z najnowocześniejszych polskich ośrodków diagnostyki i chirurgii okulistycznej, gdzie wykonuje się z powodzeniem operacje usunięcia zaćmy z wykorzystaniem lasera femtosekundowego, operacje witroretinalne oraz laserową korekcję wad wzroku. Klinika Okulistyczna OFTALMIKA w Bydgoszczy jest pierwszym ośrodkiem w Polsce, w którym w chirurgii okulistycznej wykorzystuje się szwajcarski laser femtosekundowy nowej generacji FEMTO LDV Z8 firmy Ziemer. Szeroki wachlarz wyspecjalizowanych usług: od nowoczesnej diagnostyki chorób siatkówki, nerwu wzrokowego i chorób powierzchni oka po specjalistyczne operacje okulistyczne. Ponad 30 000 wykonanych zabiegów!"

During the past decade, OFTALMIKA Sp. z o.o conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 8 clinical trials were completed, i.e. on average, 42.1% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 7 clinical trials were completed. i.e. 77.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "OFTALMIKA Sp. z o.o" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Apellis Pharmaceuticals, Inc." with 3 trials sponsored, "Kodiak Sciences Inc" with 3 trials sponsored, "Allergan" with 2 trials sponsored and "Clearside Biomedical, Inc." with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "OFTALMIKA Sp. z o.o" #1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "OFTALMIKA Sp. z o.o" are "Geographic Atrophy" (7 trials), "Diabetic Macular Edema" (3 trials), "Macular Edema" (3 trials), "Retinal Vein Occlusion" (2 trials) and "Wet Macular Degeneration" (2 trials). Many other conditions were trialed in "OFTALMIKA Sp. z o.o" in a lesser frequency.

Most popular intervention types in "OFTALMIKA Sp. z o.o" are "Drug" (18 trials), "Other" (11 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (10 trials), "Aflibercept" (6 trials), "Faricimab" (5 trials), "KSI-301" (3 trials) and "Lampalizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "OFTALMIKA Sp. z o.o" are 19 trials for "All" genders.

Currently, there are NaN active trials in "OFTALMIKA Sp. z o.o". undefined are not yet recruiting, undefined are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in OFTALMIKA Sp. z o.o, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in OFTALMIKA Sp. z o.o, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".